LOS ANGELES, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has received approval to list its common stock on the Nasdaq Global Market. Lion expects its shares to begin trading on Nasdaq on Thursday, February 26, 2015 under the company's current stock symbol "LBIO". Lion's common stock is currently listed on the OTCQB Marketplace.
Elma Hawkins, Lion's President and Chief Executive Officer, stated, "Our listing on the Nasdaq Global Market is another significant milestone for our company that we believe will allow us to raise our profile in the investment community while providing our shareholders with more effective execution on their transactions."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements, including statements regarding Lion's expectations with respect to the commencement of trading on Nasdaq and the potential effects of such listing. These statements are subject to a number of risks and uncertainties which may cause our actual results or outcomes to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include market risks and uncertainties and other risks and uncertainties described in Lion's most recent Annual Report on Form 10-K and its other filings with the SEC. Except as required by law, Lion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Investor Relations The Trout Group Tricia Truehart 646-378-2953 email@example.comSource:Lion Biotechnologies, Inc.